These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38845635)

  • 21. Pembrolizumab-induced bullous pemphigoid.
    Sun CW; Grossman SK; Aphale A; Hsu S
    JAAD Case Rep; 2019 Apr; 5(4):362-364. PubMed ID: 31008169
    [No Abstract]   [Full Text] [Related]  

  • 22. A Case of Severe Bullous Dermatitis With Mixed Bullous Pemphigoid and Pemphigus Vulgaris Cutaneous Manifestations.
    Burns RD; Vetos D; Muraga R
    Cureus; 2021 Dec; 13(12):e20433. PubMed ID: 35047270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab-Induced Lichen Planus: A Rare Immune-Related Adverse Side Effect.
    Bansal A; Singla A; Paul D; Kaur S
    Indian Dermatol Online J; 2023; 14(3):391-394. PubMed ID: 37266094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab-induced reactivation of bullous pemphigoid.
    Kaul S; Wang A; Grushchak S; Albrecht J
    Int J Dermatol; 2021 Jun; 60(6):757-758. PubMed ID: 33615441
    [No Abstract]   [Full Text] [Related]  

  • 25. Successful Outpatient Management of Diffuse Photosensitive Bullous Dermatitis Following Pembrolizumab Therapy.
    Penny C; Nath N; Kheterpal M
    J Drugs Dermatol; 2022 Jun; 21(6):668-670. PubMed ID: 35674751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid.
    Beck KM; Dong J; Geskin LJ; Beltrani VP; Phelps RG; Carvajal RD; Schwartz G; Saenger YM; Gartrell RD
    J Immunother Cancer; 2016; 4():20. PubMed ID: 27096097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab-Induced Lichenoid Dermatitis in a Patient With Metastatic Cancer of Unknown Primary.
    Sethi A; Raj M
    Cureus; 2021 Mar; 13(3):e13768. PubMed ID: 33842144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IgA bullous pemphigoid: a distinct blistering disorder. Case report and review of the literature.
    Jones RR; Goolamali SK
    Br J Dermatol; 1980 Jun; 102(6):719-25. PubMed ID: 7000138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report.
    Alshammari F; Abuzied Y; Korairi A; Alajlan M; Alzomia M; AlSheef M
    Ann Med Surg (Lond); 2022 Mar; 75():103420. PubMed ID: 35251600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid.
    Wang J; Hu X; Jiang W; Zhou W; Tang M; Wu C; Liu W; Zuo X
    Front Oncol; 2023; 13():1095694. PubMed ID: 36937423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment.
    Sugawara A; Koga H; Abe T; Ishii N; Nakama T
    J Dermatol; 2021 Mar; 48(3):401-404. PubMed ID: 33184934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Childhood benign chronic bullous dermatosis. Differential diagnosis with dermatitis herpetiformis and bullous pemphigoid].
    Casanova JM; Vives P; Hernanz JM; Cimadevilla JC; González CM
    An Esp Pediatr; 1985 Jan; 22(1):37-42. PubMed ID: 3885812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bullous pemphigoid induced by cancer immunotherapy].
    Giroud S; Chiticariu-Durr E
    Rev Med Suisse; 2020 Apr; 16(688):624-628. PubMed ID: 32239835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atypical presentations of bullous pemphigoid: Clinical and immunopathological aspects.
    Cozzani E; Gasparini G; Burlando M; Drago F; Parodi A
    Autoimmun Rev; 2015 May; 14(5):438-45. PubMed ID: 25617817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hospice health care: management of a case of bullous pemphigoid utilizing the hospice interdisciplinary team.
    Frederich M
    Hosp J; 1989; 5(2):79-83. PubMed ID: 2676821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis.
    Qiu C; Shevchenko A; Hsu S
    JAAD Case Rep; 2020 May; 6(5):400-402. PubMed ID: 32382629
    [No Abstract]   [Full Text] [Related]  

  • 37. Absence of specific histologic changes in guinea pig skin treated with bullous pemphigoid antibodies.
    Gammon WR; Briggaman RA
    J Invest Dermatol; 1988 Apr; 90(4):495-500. PubMed ID: 3280699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dyshidrosiform Bullous Pemphigoid: Case Reports and Review.
    Cohen PR
    Cureus; 2020 Jan; 12(1):e6630. PubMed ID: 32064205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bullous Pemphigoid in a Patient Treated with Pembrolizumab.
    Hara K; Yamasaki K; Yamada S; Yatera K
    Intern Med; 2020 Jan; 59(1):139-140. PubMed ID: 31511479
    [No Abstract]   [Full Text] [Related]  

  • 40. Trichoscopy - a useful tool in the preliminary differential diagnosis of autoimmune bullous diseases.
    Sar-Pomian M; Rudnicka L; Olszewska M
    Int J Dermatol; 2017 Oct; 56(10):996-1002. PubMed ID: 28856676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.